Johnson and Johnson’s group worldwide chair Sandra Peterson is set to retire at the end of September after 6 years in the role. Ms Peterson was initially given the responsibility of getting the consumer division back into profitability after a series of recalls including children’s cough drop medicine in the US. Since her tenure, the consumer-facing businesses have generated approximately £18bn in revenue for J&J.
Sandra was also responsible for the company’s global operating infrastructure and implemented innovation and growth initiatives, and has been at the helm of J&J’s healthcare technology, leveraging design thinking to create solutions for patients, consumers and providers.
“Johnson and Johnson’s group worldwide chair Sandra Peterson is set to retire at the end of September after 6 years in the role.“
Joaquin Duato, current head of J&J’s global pharmaceutical business, will share Sandra Peterson’s role with chief scientific officer Paul Stoffels after her departure. In turn Mr Duato’s role of pharma business leader will be taken over by Jennifer Taubert. Ashley McEvoy will manage the medical device companies. He made his name by breathing new life into J&J’s eye-care business. From 2nd July Kathy chief communication officer Michael Sneed and Kathy Wengel, head of manufacturing, will be promoted to J&J’s executive team.